Management of Chronic Lymphocytic Leukaemia
E Tse, H Singh Gill
Hong Kong J Radiol 2011;14(Suppl):S56-62
Chronic lymphocytic leukaemia is a disease that primarily affects the elderly and has a heterogeneous clinical course. The past decade has witnessed extensive progress in its management, owing to the generation of prognostic biological markers that influence therapeutic decisions, as well as the development of novel therapeutic agents that improve the treatment response and survival. This review discusses the value of various prognostic markers in the management of chronic lymphocytic leukaemia and the treatment options with conventional chemotherapy and newer chemoimmunotherapy regimens. However, treatment needs to be tailored to individual patients according to the patient’s general physical state, ability to tolerate treatment-related toxicity, and presence of comorbidities. To that end, an approach to formulating primary and secondary treatment decisions is also presented.
中文摘要
慢性淋巴細胞白血病的治療
謝偉財、H Singh Gill
慢性淋巴細胞白血病具臨床異質性，患者多為老年人。過去十年間對於慢性淋巴細胞白血病的治療 方法有廣泛進展，不但發現了使用預後性生物標記物來影響治療對策，還發明了新的藥物以改善患 者的治療反應及生存期。本文討論不同的預後標記物在治療慢性淋巴細胞白血病中的價值，以及使 用傳統化療及新的免疫化療的治療選擇。然而，不同的患者都須要根據其身體狀況、對治療引致的 毒性的容忍度、及其共病作出針對性的治療方案。為此，本文會提出制定初次及再次治療的決定。